Lauro Gregianin

Dr. Lauro Gregianin

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2021 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
MCMarina Curra
Marina Curra
AGAmanda F. Gabriel
Amanda F. Gabriel
MFMaria Beatriz C. Ferreira
Maria Beatriz C. Ferreira
MMMarco Antonio T. Martins
Marco Antonio T. Martins
ABAndre Brunetto
Andre Brunetto
MMManoela Domingues Martins
Manoela Domingues Martins

7 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ATAmanda Thomaz
Amanda Thomaz
MJMariane da Cunha Jaeger
Mariane da Cunha Jaeger
ABAlgemir L. Brunetto
Algemir L. Brunetto
ABAndre Brunetto
Andre Brunetto
LGLauro Gregianin
Lauro Gregianin
Rafael Roesler RoeslerRafael Roesler Roesler
Rafael Roesler Roesler
Neurotrophins are a family of secreted proteins that act by binding to tropomyosin receptor kinase (Trk) or p75NTR receptors to regulate nervous system development and plasticity. Increasing evidence indicates that neurotrophins and their receptors in cancer cells play a role in tumor growth and resistance to treatment. In this review, we summarize evidence indicating that neurotrophin signaling influences medulloblastoma (MB), the most common type of malignant brain cancer afflicting children. We discuss the potential of neurotrophin receptors as new therapeutic targets for the treatment of MB. Overall, activation of TrkA and TrkC types of receptors seem to promote cell death, whereas TrkB might stimulate MB growth, and TrkB inhibition displays antitumor effects. Importantly, we show analyses of the gene expression profile of neurotrophins and their receptors in MB primary tumors, which indicate, among other findings, that higher levels of NTRK1 or NTRK2 are associated with reduced overall survival (OS) of patients with SHH MB tumors.

20 August 2020 in International Journal of Paediatric Dentistry
Verified
Journal Article
Closed access
PDF file
JVJéssica Berté Valer
Jéssica Berté Valer
MCMarina Curra
Marina Curra
AGAmanda de Farias Gabriel
Amanda de Farias Gabriel
TSTuany Rafaeli Schmidt
Tuany Rafaeli Schmidt
MFMaria Beatriz Cardoso Ferreira
Maria Beatriz Cardoso Ferreira
LGLauro Gregianin
Lauro Gregianin

9 September 2019 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
JMJuliana Kern de Moraes
Juliana Kern de Moraes
VWVivian Petersen Wagner
Vivian Petersen Wagner
FFFelipe Paiva Fonseca
Felipe Paiva Fonseca
GAGleyson Kleber do Amaral-Silva
Gleyson Kleber do Amaral-Silva
CFCaroline Brunetto de Farias
Caroline Brunetto de Farias
MMManoela Domingues Martins
Manoela Domingues Martins

1 July 2020 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
CJClaudio Galvao de Castro Jr.
Claudio Galvao de Castro Jr.
LGLauro Gregianin
Lauro Gregianin
JBJan A. Burger
Jan A. Burger
(2020). Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. Leukemia & Lymphoma. Ahead of Print.

16 November 2019 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
FCFABIANNE ALTRUDA DE MORAES COSTA CARLESSE
FABIANNE ALTRUDA DE MORAES COSTA CARLESSE
LDLiane Daudt
Liane Daudt
ASAdriana Seber
Adriana Seber
ÁDÁlvaro Pimenta Dutra
Álvaro Pimenta Dutra
AMAnaly Melo
Analy Melo
Arnaldo L. ColomboArnaldo L. Colombo
Arnaldo L. Colombo
In the present paper we summarize the suggestions of a multidisciplinary group including experts in pediatric oncology and infectious diseases who reviewed the medical literature to elaborate a consensus document (CD) for the diagnosis and clinical management of invasive fungal diseases (IFDs) in children with hematologic cancer and those who underwent hematopoietic stem-cell transplantation. All major multicenter studies designed to characterize the epidemiology of IFDs in children with cancer, as well as all randomized clinical trials addressing empirical and targeted antifungal therapy were reviewed. In the absence of randomized clinical trials, the best evidence available to support the recommendations were selected. Algorithms for early diagnosis and best clinical management of IFDs are also presented. This document summarizes practical recommendations that will certainly help pediatricians to best treat their patients suffering of invasive fungal diseases.